Insider Cluster (3 insiders) ·Filed Mar 25, 2026

NUVL

Nuvalent, Inc.
BEARISH
Impact 7/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $1.7M total
Actionable Insight ▼ Bearish

Coordinated selling by multiple C-suite executives, especially the CFO, signals potential lack of confidence in near-term prospects. Traders should monitor upcoming earnings, pipeline updates, or clinical trial data for downward revisions or delays that may not yet be public.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
NUVL ▲ +25.94% at T+60d
SHORT call ✗ call lost -25.94% · α vs SPY -12.49% · entry $98.00 → $123.43
Entry anchored
Mar 24, 03:59 PM ET
via exchange tick
T+1d
+0.06%
call -0.06% · α -1.83%
$98.06
settled 6mo ago
T+5d
+7.80%
call -7.80% · α -8.04%
$105.64
settled 6mo ago
T+20d
+10.22%
call -10.22% · α -2.36%
$108.02
settled 5mo ago
T+60d
+25.94%
call -25.94% · α -12.49%
$123.43
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Three C-suite executives at Nuvalent sold a combined $1.71M in shares over a 7-day period, including CFO Alexandra Balcom who sold $1.37M — the largest individual transaction. These were open-market sales, not tax-related or non-cash events, and represent a coordinated exit by senior insiders.

Key Financial Metrics

Direction
selling
Total Value
$1.7M
Insiders
3

Key Facts

  • CFO Alexandra Balcom sold 13,700 shares for $1.37M at $100.16 per share on March 25, 2026
  • Chief Development Officer Darlene Noci sold 2,532 shares for $246,693 at $97.43 on March 30, 2026
  • Chief Legal Officer Deborah Miller sold 940 shares for $91,650 at $97.50 on March 26, 2026
  • Total open-market sales: $1.71M across three C-suite executives in seven days
  • Non-cash derivative exercises also occurred but are not economically significant

Financial Impact

$1.71M in insider selling by C-suite executives, representing 0.021% of Nuvalent's $8.1B market cap

insider sentimentshareholder confidencepotential dilution risk

Risk Factors

  • Insider selling may precede negative news such as clinical trial setbacks or funding challenges
  • Perception of weakening leadership confidence could pressure stock despite small absolute size of sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NUVL-1775075501840
18 reports for NUVL
Performance horizon
43% Hit rate 3 of 7 directional calls best @ T+60▲ +21.01%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
15-12G
NEUTRAL ★ 3/10
—awaiting T+5——
Jul 15, 2026
11w ago
25-NSE
NEUTRAL ★ 3/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 15, 2026
11w ago
8-K
BULLISH ★ 5/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.80 $123.96▲ +0.13%▼ −0.73%—
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.72 $123.90▲ +0.15%▼ −0.34%—
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$123.25 $123.43▲ +0.15%▼ −0.53%—
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.45 $123.36▼ −0.07%▼ −0.51%—
Jun 9, 2026
16w ago
8-K
BULLISH ★ 8/10
$123.25 $123.35▲ +0.08%▼ −2.33%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$102.40 $105.22▲ +2.75%▲ +1.25%—
Apr 29, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $101.47▲ +2.39%▼ −0.72%—
Showing 10 of 18

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 1, 2026